Optimizing Blood Stem Cell Transplants for Blood C cancers and related diseases
Official title: Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies
Funded at Washington University · NIH-11370616 · Data updated 2026-11-12
This grant supports improving how stem cell transplants are collected and given, with the goal of better outcomes and fewer side effects for people with blood cancers and some autoimmune or inherited conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 7, 2017 |
| Project end | June 30, 2032 |
| Funding year | 2026 |
| Award (this year) | $771,991 |
| NIH project number | 5R35CA210084-09 |
| Project ID | NIH-11370616 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with hematological malignancies or selected non-malignant conditions who are candidates for hematopoietic stem cell transplantation and participate in related clinical trials at the institution.
✕Less likely to help
Patients not undergoing transplant or not enrolled in related trials may not directly benefit from these translational advances.
What this research studies
This project aims to overcome key hurdles in hematopoietic stem cell transplantation, such as obtaining sufficient stem cells for transplant and reducing treatment-related toxicity. It follows a translational path, building on decades of clinical trials and real-world experiences to improve conditioning, graft-versus-host disease management, and relapse prevention. The research team has already contributed to FDA-approved therapies and first-in-human CAR-T cell work, signaling a strong track record in moving promising strategies to patients. The work will likely involve correlative studies alongside ongoing or upcoming clinical trials at Washington University. Overall, the project seeks to translate scientific insights into safer, more effective stem cell transplant protocols for patients.
Why it matters
Potential benefit: If successful, patients could experience safer transplant procedures, better disease control, and fewer complications from graft-versus-host disease and treatment toxicities.
How similar studies have gone: Previous efforts have led to FDA-approved therapies and first-in-human trials, indicating that translating this approach can yield meaningful clinical benefits.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Dipersio, John F. — Washington University
- Study coordinator: Dipersio, John F.
Related research
Other NIH-funded projects on the same topics.
-
Improving Stem Cell Transplants for Blood Cancers and Other Diseases
This work aims to make stem cell transplants safer and more effective for people with blood cancers, autoimmune diseases, and other serious conditions.
-
Gentle electrical stimulation to keep muscles strong during stem cell transplant
This project uses small, gentle electrical pulses to try to help Veterans keep muscle strength and reduce fatigue during and after stem cell transplants for blood cancers.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Inpatient yoga therapy for cancer patients undergoing stem cell transplant
A randomized trial will test whether an inpatient yoga program helps people receiving stem cell transplants feel better and cope with treatment.
-
A structured peer support program for people having stem cell transplants
A brief, supportive, phone-based peer program for adults with blood cancers undergoing stem cell transplant to help manage stress and improve recovery.
-
Disrupting BM niches and boostingCAR-T therapy in blood cancers
A program at Washington University is developing better ways to collect stem cells for transplantation, reduce graft-versus-host disease, and improve CAR-T cell therapies for blood cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.